Monash University has spun out Cincera Therapeutics, which will work on treatments for metabolic syndrome and type-2 diabetes-related conditions.
Cincera Therapeutics, an Australia-based drug developer, was spun out from Monash University with A$7m ($5.5m) in funding provided by the Medical Research Commercialisation Fund (MRCF).
Cincera is developing therapies for a wide range of conditions, such as metabolic syndrome, type-2 diabetes-related diseases and certain cancers. The technology relies on identifying and targeting enzymes of fat metabolism that contribute to disease.
The spinout is based on research by Bernard Flynn, associate professor at Monash University’s Institute of Pharmaceutical Sciences, and Stuart…
